[go: up one dir, main page]

UY39484A - Inhibidores de interleucina-17 - Google Patents

Inhibidores de interleucina-17

Info

Publication number
UY39484A
UY39484A UY0001039484A UY39484A UY39484A UY 39484 A UY39484 A UY 39484A UY 0001039484 A UY0001039484 A UY 0001039484A UY 39484 A UY39484 A UY 39484A UY 39484 A UY39484 A UY 39484A
Authority
UY
Uruguay
Prior art keywords
interleukin
inhibitors
formamido
pyridyl
pyridine
Prior art date
Application number
UY0001039484A
Other languages
English (en)
Inventor
David Orain
Thomas Josef Troxler
Pascal Furet
Klaus Weigand
Achim Schlapbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY39484A publication Critical patent/UY39484A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de 2-formamido (N-fenil y N-piridil) acetamida sustituidos con N-óxidos de piridina que son inhibidores de interleucina-17 (IL-17), a procesos para su preparación, composiciones farmacéuticas, y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por IL-17.
UY0001039484A 2020-11-02 2021-10-25 Inhibidores de interleucina-17 UY39484A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20205121 2020-11-02

Publications (1)

Publication Number Publication Date
UY39484A true UY39484A (es) 2022-06-30

Family

ID=73059405

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039484A UY39484A (es) 2020-11-02 2021-10-25 Inhibidores de interleucina-17

Country Status (20)

Country Link
US (1) US20230391782A1 (es)
EP (1) EP4237417A1 (es)
JP (1) JP7608604B2 (es)
KR (1) KR20230091945A (es)
CN (1) CN116323596A (es)
AR (1) AR123962A1 (es)
AU (1) AU2021368247B2 (es)
CA (1) CA3190738A1 (es)
CL (1) CL2023001220A1 (es)
CO (1) CO2023005280A2 (es)
CR (1) CR20230180A (es)
DO (1) DOP2023000081A (es)
EC (1) ECSP23030375A (es)
IL (1) IL302447A (es)
MX (1) MX2023005076A (es)
PE (1) PE20231047A1 (es)
SA (1) SA523440574B1 (es)
TW (1) TW202227408A (es)
UY (1) UY39484A (es)
WO (1) WO2022091056A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
US20250197378A1 (en) 2022-03-04 2025-06-19 Leo Pharma A/S Small molecule modulators of il-17
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US20050070567A1 (en) 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
RU2644651C2 (ru) 2010-04-26 2018-02-13 Новартис Аг Среда для культивирования клеток
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
WO2013150416A1 (en) * 2012-04-06 2013-10-10 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
WO2014065791A1 (en) 2012-10-24 2014-05-01 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
AP2015008584A0 (en) 2013-02-08 2015-07-31 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
EP3538513A1 (en) * 2016-11-11 2019-09-18 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
WO2019136147A1 (en) * 2018-01-03 2019-07-11 The Board Of Trustees Of The University Of Illinois Toll-like receptor signaling inhibitors
US11472794B2 (en) * 2018-01-15 2022-10-18 UCB Biopharma SRL Fused imidazole derivatives as IL-17 modulators
GB201820166D0 (en) * 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
CA3121719A1 (en) * 2018-12-19 2020-06-25 Leo Pharma A/S Amino-acid anilides as small molecule modulators of il-17
BR112022023983A2 (pt) * 2020-05-27 2022-12-20 Sanofi Sa Compostos terapêuticos
BR112022024045A2 (pt) * 2020-05-27 2022-12-20 Sanofi Sa Moduladores il-17a

Also Published As

Publication number Publication date
DOP2023000081A (es) 2023-06-15
AU2021368247A9 (en) 2023-10-05
CL2023001220A1 (es) 2023-12-22
CA3190738A1 (en) 2022-05-05
EP4237417A1 (en) 2023-09-06
CN116323596A (zh) 2023-06-23
AR123962A1 (es) 2023-01-25
MX2023005076A (es) 2023-05-16
WO2022091056A1 (en) 2022-05-05
JP2023547470A (ja) 2023-11-10
PE20231047A1 (es) 2023-07-11
AU2021368247B2 (en) 2023-10-05
IL302447A (en) 2023-06-01
CR20230180A (es) 2023-05-25
CO2023005280A2 (es) 2023-05-19
ECSP23030375A (es) 2023-05-31
TW202227408A (zh) 2022-07-16
AU2021368247A1 (en) 2023-05-18
US20230391782A1 (en) 2023-12-07
KR20230091945A (ko) 2023-06-23
JP7608604B2 (ja) 2025-01-06
SA523440574B1 (ar) 2024-10-20

Similar Documents

Publication Publication Date Title
UY39484A (es) Inhibidores de interleucina-17
CL2022000201A1 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
CL2023003583A1 (es) Inhibidores de pi3k y métodos de uso de los mismos div 2985-22
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
CR20230507A (es) Anticuerpos anti-il-2r agonistas y métodos de uso
CL2022002963A1 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CO2024011162A2 (es) Inhibidores de nlrp3
MX2023009874A (es) Anticuerpos anti-psma y estructuras car-t.
MX2024013040A (es) Pirfenidona enriquecida con deuterio y metodos para su uso
CL2023003073A1 (es) Anticuerpos anti-cd20 y estructuras car-t
CR20230259A (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
CO2018012020A2 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
MX2021007032A (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos.
CL2023002821A1 (es) Derivados de tetrahidrotieno piridina como inhibidores de ddr